Skip to main content
    C

    Corvus Pharmaceuticals Inc (CRVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.60
    -0.04 (-0.38%)

    Market Cap: $897.52M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Corvus Pharmaceuticals Inc (CRVS) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Corvus Pharmaceuticals (CRVS) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Corvus Pharmaceuticals reported EPS of -$0.22, below the -$0.21 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    40%(16/40)
    Avg Surprise
    -12.53%

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.24
    Range-$0.28 - -$0.19
    9 analysts
    Revenue Consensus
    N/A
    RangeN/A
    8 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.27
    Range-$0.29 - -$0.25
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.26-2.5%
    60d ago-$0.26-2.5%
    30d ago-$0.26-2.5%
    7d ago-$0.26-2.5%
    Current-$0.27
    Revenue Consensus
    N/A
    RangeN/A
    3 analysts

    Next Report

    CRVS has an expected report date of Mar 10, 2027.

    CRVS Earnings Call

    The latest CRVS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CRVS beat 16, missed 17 and matched 7. The widest gap in the table came in the quarter ended Sep 30, 2024, when EPS landed 400.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.22-$0.21-$0.22 - -$0.18-4.76%MissN/A40 up, 3 downNov 5, 2026N/A
    Jun 30, 2026-$0.19-$0.17-$0.20 - -$0.15-11.76%MissN/A40 up, 3 downAug 6, 2026N/A
    Mar 31, 2026-$0.15-$0.15-$0.17 - -$0.140.00%In lineN/A30 up, 2 downMay 7, 2026N/A
    Dec 31, 2025-$0.15-$0.13-$0.15 - -$0.12-18.48%MissN/A41 up, 0 downMar 12, 2026N/A
    Sep 30, 2025-$0.12-$0.13-$0.14 - -$0.13+7.69%BeatN/A41 up, 2 downNov 4, 2025N/A
    Jun 30, 2025-$0.10-$0.13-$0.16 - -$0.10+23.08%BeatN/A51 up, 2 downAug 7, 2025N/A
    Mar 31, 2025-$0.14-$0.12-$0.13 - -$0.10-16.67%MissN/A41 up, 0 downMay 8, 2025N/A
    Dec 31, 2024-$0.14-$0.12-$0.13 - -$0.10-19.08%MissN/A50 up, 1 downMar 25, 2025$88000
    Sep 30, 2024-$0.60-$0.12-$0.14 - -$0.10-400.00%MissN/A40 up, 0 downNov 12, 2024N/A
    Jun 30, 2024-$0.07-$0.11-$0.12 - -$0.11+36.36%BeatN/A41 up, 0 downAug 6, 2024N/A
    Mar 31, 2024-$0.12-$0.13-$0.15 - -$0.12+7.69%BeatN/A20 up, 0 downMay 6, 2024N/A
    Dec 31, 2023-$0.14-$0.12-$0.13 - -$0.10-16.67%MissN/A40 up, 0 downMar 19, 2024$246000
    Sep 30, 2023-$0.12-$0.12-$0.18 - -$0.060.00%In lineN/A40 up, 0 downNov 7, 2023N/A
    Jun 30, 2023-$0.14-$0.14-$0.18 - -$0.110.00%In lineN/A40 up, 0 downAug 8, 2023N/A
    Mar 31, 2023-$0.17-$0.17-$0.19 - -$0.130.00%In lineN/A30 up, 0 downMay 8, 2023N/A
    Dec 31, 2022-$0.21-$0.23-$0.25 - -$0.21+8.70%BeatN/A30 up, 0 downMar 28, 2023N/A
    Sep 30, 2022-$0.32-$0.14-$0.18 - -$0.13-128.57%MissN/A30 up, 0 downNov 3, 2022$147000
    Jun 30, 2022-$0.18-$0.18-$0.19 - -$0.160.00%In lineN/A30 up, 0 downAug 8, 2022$146000
    Mar 31, 2022-$0.18-$0.15-$0.16 - -$0.14-20.00%MissN/A30 up, 0 downMay 5, 2022$146000
    Dec 31, 2021-$0.20-$0.19-$0.21 - -$0.17-5.26%MissN/A40 up, 0 downMar 10, 2022$141000
    Sep 30, 2021-$0.24-$0.24-$0.35 - -$0.180.00%In lineN/A30 up, 0 downNov 1, 2021$94000
    Jun 30, 2021-$0.28-$0.31-$0.36 - -$0.27+9.68%BeatN/A3N/AAug 2, 2021N/A
    Mar 31, 2021-$0.34-$0.31-$0.36 - -$0.27-9.68%MissN/A3N/AApr 29, 2021N/A
    Dec 31, 2020-$0.33-$0.32-$0.41 - -$0.24-3.13%MissN/A4N/AMar 25, 2021N/A
    Sep 30, 2020-$0.33-$0.22-$0.33 - -$0.18-50.00%MissN/A5N/AOct 29, 2020N/A
    Jun 30, 2020-$0.36-$0.24-$0.43 - -$0.20-50.00%MissN/A5N/AJul 30, 2020N/A
    Mar 31, 2020-$0.44-$0.40-$0.42 - -$0.37-10.00%MissN/A5N/AApr 30, 2020N/A
    Dec 31, 2019-$0.38-$0.33-$0.38 - -$0.29-15.15%MissN/A4N/AMar 5, 2020N/A
    Sep 30, 2019-$0.37-$0.43-$0.45 - -$0.38+13.95%BeatN/A4N/AOct 29, 2019N/A
    Jun 30, 2019-$0.44-$0.44-$0.47 - -$0.420.00%In lineN/A4N/AAug 1, 2019N/A
    Mar 31, 2019-$0.40-$0.48N/A+16.67%BeatN/A2N/AMay 9, 2019N/A
    Dec 31, 2018-$0.36-$0.46-$0.59 - -$0.39+21.74%BeatN/A3N/AMar 7, 2019N/A
    Sep 30, 2018-$0.36-$0.49-$0.53 - -$0.45+26.53%BeatN/A4N/ANov 1, 2018N/A
    Jun 30, 2018-$0.40-$0.61-$0.66 - -$0.51+34.43%BeatN/A4N/AAug 2, 2018N/A
    Mar 31, 2018-$0.63-$0.77-$0.86 - -$0.62+18.18%BeatN/A5N/AMay 3, 2018N/A
    Dec 31, 2017-$0.58-$0.77-$0.92 - -$0.66+24.68%BeatN/A5N/AMar 1, 2018N/A
    Sep 30, 2017-$0.62-$0.84-$0.90 - -$0.74+26.19%BeatN/A5N/ANov 2, 2017N/A
    Jun 30, 2017-$0.73-$0.74-$0.90 - -$0.58+1.35%BeatN/A5N/AAug 3, 2017N/A
    Mar 31, 2017-$0.79-$0.77N/A-2.60%MissN/AN/AN/AMay 4, 2017N/A
    Dec 31, 2016-$0.55-$0.57N/A+3.51%BeatN/AN/AN/AMar 10, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.51, after -$0.93 the year before. It was -$6.88 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.51N/A
    Dec 31, 2024-$0.93N/A
    Dec 31, 2023-$0.57N/A
    Dec 31, 2022-$0.89N/A
    Dec 31, 2021-$1.06N/A
    Dec 31, 2020-$1.46N/A
    Dec 31, 2019-$1.59N/A
    Dec 31, 2018-$1.75N/A
    Dec 31, 2017-$2.72N/A
    Dec 31, 2016-$6.88N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,8259
    2026Q2Jun 30, 20264,48410
    2025Q4Dec 31, 20255,81811
    2025Q3Sep 30, 20255,08611
    2025Q2Jun 30, 20253,5697
    2025Q1Mar 31, 20255,31010
    2024Q4Dec 31, 20244,23011
    2024Q3Sep 30, 20245,3349

    2026Q3 Earnings Call

    Opening remarks

    Zack Kubow Vice President, Investor Relations and Corporate Communications Thank you, operator, and good afternoon, everyone. Thanks for joining us for the Corvus Pharmaceuticals third quarter 2026 business update and financial results conference call. On the call to discuss the results and business updates are Richard A. Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; Jeffrey Arcara, Chief Business Officer; Ben Jones, Senior Vice President of Pharmaceutical Development; and Suresh Mahadevan, Vice President of Clinical Development. The executive team will open the call with some prepared remarks, followed by a question-and-answer period. I would like to remind everyone that comments made by management today and in answer to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today, and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in the Corvus quarterly report on Form 10-Q for the quarter ended September 30, 2026, and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law. With that, I would like to turn the call over to Leiv Lea. Leiv?

    Leiv Lea Chief Financial Officer Thank you, Zack. I will begin with a brief overview of our third quarter 2026 financials and then turn the call over to Richard for a business update. Research and development expenses in the third quarter of 2026 totaled $17.8 million, compared to $8.5 million for the same period in 2025. The increase in R&D expenses was primarily due to higher clinical trial costs associated with the development of soquelitinib, as well as an increase in personnel costs. Net loss for the third quarter of 2026 was $20.3 million, compared to a net loss of $10.2 million for the same period in 2025. Included in the net loss for the third quarter of 2026 and 2025 were noncash losses of $0.9 million and $0.3 million, respectively, from Corvus' equity method investment in Angel Pharmaceuticals. Total stock compensation expense for the three months ended September 30, 2026 was $2.8 million, compared to $1.2 million for the same period in 2025. As of September 30, 2026, Corvus had cash, cash equivalents, and marketable securities totaling $202.9 million, compared to $56.8 million at December 31, 2025. Cash as of September 30, 2026 included approximately $189.4 million in net proceeds received in a follow-on offering completed in Q1. Also, as announced on June 9, 2026, Corvus invested $5 million in a $13.5 million financing completed by Angel Pharmaceuticals in the second quarter of 2026.

    Frequently Asked Questions About CRVS

    When is Corvus Pharmaceuticals's next earnings date?

    Corvus Pharmaceuticals's next earnings report is expected for Mar 10, 2027.

    Did CRVS beat earnings estimates last quarter?

    No. Corvus Pharmaceuticals reported EPS of -$0.22 for the quarter ended Sep 30, 2026, below the -$0.21 estimate by 4.76%.

    What EPS do analysts expect from CRVS next quarter?

    The consensus EPS estimate for Corvus Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.24 from 9 analysts, with estimates from -$0.28 to -$0.19.

    How often does CRVS beat earnings estimates?

    Corvus Pharmaceuticals beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -5.00%.